Colorectal Cancer

A study in JAMA evaluated whether adding high-dose vitamin D3 to standard chemotherapy improves PFS in patients with advanced or metastatic colorectal cancer.

A phase III trial examined immunotherapy in patients with microsatellite-stable metastatic colorectal cancer.

Researchers evaluated a “watch and wait” strategy that includes chemotherapy and radiation, but not surgery, in carefully selected patients with rectal cancer.

An oncology pharmacist discusses how to prevent and treat the toxicities from regorafenib for the treatment of colorectal cancer.

Investigators studied a combination of pertuzumab and trastuzumab in patients with metastatic, HER2-positive colorectal cancer.

Research published in Cancer evaluated whether colorectal cancers diagnosed in early adulthood differ from those diagnosed at older ages.

Here, we look at the currently open and recruiting clinical trials that focus on the role of the microbiome in colorectal cancer.

Cancer Network spoke with Dr. Scott Kopetz about RNA-based subtyping and the challenge of spreading the word of the importance of biomarker testing in colorectal cancer.

A recent study identified a new biomarker in colorectal cancers that may assist in early detection of the disease.

Cancer Network spoke with Dr. Michael Holick about the role of and effectiveness of vitamin D in cancer prevention.

Researchers tested whether the combination of durvalumab and tremelimumab could improve survival over best supportive care in patients with advanced refractory colorectal cancer.

Researchers tested an antigen-specific cancer vaccine known as tecemotide vs placebo in patients with colorectal cancer and liver metastases to see if outcomes would be improved.

Negative colonoscopy results in patients with average CRC risk were associated with a lower risk for CRC diagnosis and death more than a decade after the test.

The XELAVIRI trial failed to demonstrate the noninferiority of a sequential escalation treatment strategy vs initial combination therapy in mCRC.

Microsatellite instability and or mismatch repair deficiency found predictive of LS across a broader tumor spectrum than previously thought.

A study takes a closer look at colorectal cancer screening incentives among New York State Medicaid managed care patients.

A study looks at how dietary patterns impact colorectal cancer outcomes before and after diagnosis.

Dr. Luis Diaz spoke with Cancer Network about monitoring for residual disease in colon cancer ahead of his presentation at ESMO 2018.

Until recent studies were reported, immunotherapy was thought to be ineffective for colorectal cancer; this article provides guidance on how to incorporate immunotherapy into this setting.

A study of an equal-access military health system shows universal health insurance for both the military and civilian populations could improve CRC screening rates.

A study shows ZEB2 has clinical potential and may improve TNM risk-stratification and guide treatment in colorectal cancer.

In this article, we review the findings of the IDEA study and discuss the optimal duration of oxaliplatin-based adjuvant chemotherapy using patient-based risk factors.

A study finds tailored phone intervention significantly increases colorectal cancer screening compared to usual care.

It may be possible to predict personalized tumor progression in CRC patient's liquid biopsy and mathematical modeling.

Patients treated with anti–PD-1 or anti–PD-L1 inhibitors in clinical trials were successfully retreated with the inhibitors after discontinuing the treatment.